Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03778996Phase 2Active Not Recruiting

SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Role: collaborator

NCT03512756Phase 2Terminated

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

Role: lead

NCT04720664Phase 2Terminated

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Role: collaborator

NCT02562612Phase 1Withdrawn

Study of SM-88 in Advanced Cancers

Role: lead

NCT02796898Phase 1Completed

Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer

Role: lead

All 5 trials loaded